GET DAILY SIGNALSSenti Biosciences (SNTI) Q3 2026 Earnings: Watching Liquidity and Clinical Progress
Key Takeaways
- Senti Biosciences is expected to report third-quarter 2026 results in mid-November, with consensus estimates pointing to a net loss of roughly $0.21 per share.
- Revenue is forecast to remain minimal — near zero — reflecting the company's status as a clinical-stage biotechnology firm with no approved commercial product.
- Investors will focus heavily on the company's cash position and its "going concern" warning, which management has flagged given limited operating capital.
- The company's lead candidate, SENTI-202, a gene-circuit CAR-NK cell therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), remains the key clinical driver.
- A strategic transformation — including a plan to divest clinical assets in exchange for contingent value rights (CVRs, which entitle holders to future payments if specific milestones are met) — will be a major topic of discussion.
Why This Report Matters Now
Senti Biosciences' upcoming report carries outsize importance because it arrives at a pivotal moment for a company navigating both clinical progress and financial pressure. The firm is advancing SENTI-202 toward a pivotal phase after receiving supportive feedback from the U.S. Food and Drug Administration (FDA), yet it has simultaneously warned of "substantial doubt" about its ability to continue as a going concern without additional funding. With cash having declined from $16.4 million at the end of 2025 to roughly $8.9 million by March 2026, and then further during the second quarter, this report will be read primarily as a checkpoint on liquidity and on the progress of its strategic restructuring, rather than as a conventional revenue story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Are Expected to Show
For the third quarter of 2026, consensus analyst estimates project a net loss of approximately $0.21 per share, though individual estimates in circulation range from about $0.21 to $0.38 per share of losses. Revenue expectations are essentially immaterial, with most forecasts near zero, consistent with a pre-revenue clinical-stage company whose collaboration income has been minimal. For context, the company reported a loss of $0.41 per share in the second quarter of 2026, missing the consensus estimate of roughly $0.33, and a loss of $0.14 per share in the first quarter, which beat expectations. The stock has historically been volatile around earnings, with post-report moves reflecting sentiment on cash runway and clinical updates as much as headline numbers.
Market Sentiment Heading Into the Print
Sentiment heading into this report is cautious. Senti Biosciences shares have fallen sharply over the past year, reflecting the combined weight of dilution, ongoing losses, and the company's financing uncertainty. The second-quarter results and the accompanying disclosure of a strategic pivot — including a definitive merger agreement to divest clinical assets in exchange for contingent value rights — added complexity to the equity story, and investors will be watching for clarity on that transaction's status. Key risk factors include the pace of cash consumption, the terms and timing of any additional financing, and whether the company can sustain operations while its restructuring proceeds. Given the stock's elevated volatility, the report could trigger a notable move in either direction.
Forward-Looking Items Worth Tracking
Beyond the headline loss per share, investors should track several forward-looking items. First, watch the company's disclosed cash balance and any updated runway guidance, as management previously indicated that current capital may only fund operations for a limited number of quarters without new financing.
Second, monitor developments tied to the proposed divestiture of clinical assets and the associated contingent value rights. The structure, timing, and milestone conditions of that transaction will materially shape how shareholders evaluate the company's remaining value.
Third, follow any clinical updates on SENTI-202. Positive FDA engagement supporting a pivotal trial in relapsed or refractory AML remains the most important long-term catalyst for the underlying technology, even as the corporate structure evolves.
Finally, pay attention to operating-expense trends. Recent quarters showed meaningful reductions in research and development (R&D) and general and administrative (G&A) spending, and continued discipline will be essential to extending the runway. As always, these factors should be weighed alongside the inherent risks of clinical-stage biotechnology investing. From what I see, the AI Trend Prediction Engine can help put some of these longer-term clinical milestones in context when reviewing the broader sector.
Using Tickeron Tools for Earnings Prep
In my view, having reliable screening and signal tools makes it easier to stay on top of names like this ahead of events. I regularly turn to Tickeron’s AI Screener when preparing for reports like the one coming from Senti Biosciences. It lets me quickly filter for comparable clinical-stage companies, review volatility patterns, and spot any technical setups that might influence how the market reacts. The platform’s customizable filters save time and help focus attention on the metrics that matter most for a given quarter.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SNTI in -12.12% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 273 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNTI as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Aroon Indicator for SNTI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SNTI's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for SNTI just turned positive on November 11, 2026. Looking at past instances where SNTI's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.498). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement